Pfizer

ZIRABEV

View Prices
  1. Home
    2.  / 
  2. Q Code
    3.  / ZIRABEV – Q5118

Manufacturer:

Pfizer

Name:

ZIRABEV

HCPCS Code Descriptor:

Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg

Category:

Q Code

HCPCS:

Q5118

NDC(s):

00069-0315-01, 00069-0342-01

Primary Type:

Oncology Biosimilar

Generic Status:

Single-Source

Route of Administration:

Intravenous

About:

ZIRABEV is an Oncology Biosimilar drug manufactured by Pfizer and administered via the Intravenous route of administration. The Q Code: Q5118 is aligned to the drug ZIRABEV.

Zirabev (bevacizumab) is a VEGF (Vascular Endothelial Growth Factor) protein inhibitor used to treat various types of cancer. This includes colorectal cancer, non-small cell lung cancer, renal cell carcinoma, cervical cancer, and certain types of brain tumors, among other types of cancer. Zirabev is manufactured by Pfizer and is biosimilar to Avastin (J9035). This medication is aligned to the HCPCS code Q5118 and has been since October 2019.

View Prices

Access Pricing and More By Registering

Register Now

HCPCS Added Date:

10/1/19

HCPCS Effective Date:

10/1/19

HCPCS Short Description:

Inj., zirabev, 10 mg

Billing and Coding Guide:

https://www.pfizeroncologytogether.com/files/ZIRABEV_Billing_and_Coding_Guide.pdf

Patient Assistance:

Not Found